RWE Strategy for Lean Pharma Teams: How Small and Mid-Size Companies Can Leverage Real-World Evidence Without an Internal Function
You’re the Head of Market Access at a 200-person specialty biotech. Your lead asset is 18 months from a potential
Loss of Exclusivity in Pharma: Forecasting, Modeling and Market Impact Insights
Every pharma commercial leader knows the feeling. You’ve spent years building a blockbuster brand, navigating market access hurdles, defending your
Loss of Exclusivity in Pharma: Forecasting, Modeling and Market Impact Insights Read Post »
Diagnosed Prevalence and Patient Data Solutions for Pharma
When pharma market access directors ask me about the biggest gap in their evidence strategy, it’s almost always the same
Diagnosed Prevalence and Patient Data Solutions for Pharma Read Post »